Nachrichten zur Vertex Pharmaceuticals Inc. Aktie

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $492.69, signifying a -1.96% move from its prior days close.…

Vertex Pharmaceuticals (VRTX) closed at $502.55 in the latest trading session, marking a +0.45% move from the prior day.…

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to…

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close.…

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $512.52, indicating a +0.06% shift from the previous trading…

Equity markets started 2025 pretty well, but things havent been so rosy in the past couple of months. The tech-heavy…

Vertex Pharmaceuticals (VRTX) ist als Marktführer zur Behandlung von zystische Fibrose (CF) bisher stark vom Kernprodukt TRIKAFTA mit 93 %…

Are you reluctant to invest in stocks right now? Thats understandable. Fear, uncertainty, and doubt have become the norm in…

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior days close.…

Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its…

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first…

There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their hard-earned money into…

Am 07. März 2025 gab Vertex Pharmaceuticals Inc. bekannt, dass die britische Regulierungsbehörde für Arzneimittel und Gesundheitsprodukte (MHRA) die Zulassung…

Its often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We…

2025 has gotten off to a choppy start as some of the most valuable U.S.-based companies are dragging down the…

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the…

Dr. Reshma Kewalramani, Vertex Pharmaceuticals CEO, leads the first biotech to win approval for a therapy using CRISPR gene editing…

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks…

Looking for a good area in which to invest? Consider the healthcare sector. People must have healthcare. And with aging…

If youre content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not,…

Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the worlds leading drugmakers, missed last years strong market rally.…

Healthcare isnt the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months,…

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for…

Vancouver (www.aktiencheck.de) - Rating-Update: Canaccord hat die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol: VX1, NASDAQ-Symbol: VRTX) von…

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the…

New York (www.aktiencheck.de) - Rating-Update: Terence Flynn, Analyst von Morgan Stanley, stuft die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN:…

Heres our initial take on Vertex Pharmaceuticals (NASDAQ: VRTX) fourth-quarter financial report. Key Metrics Metric Q4 2023 Q4 2024 Change vs. Expectations Revenue $2.52 billion $2.91 billion 16% Beat Earnings per share $3.71 $3.50 -6% Missed Trikafta/Kaftrio…

Das US-Biotech-Unternehmen Vertex Pharmaceuticals hat am Montag nach US-Börsenschluss seine Zahlen für das vierte Quartal vorgelegt. Beim Umsatz konnte Vertex…

Das US-Biotech-Unternehmen Vertex Pharmaceuticals hat am Montag nach US-Börsenschluss seine Zahlen für das vierte Quartal vorgelegt. Beim Umsatz konnte Vertex…

VRTX earnings call for the period ending December 31, 2024.…

…

Vertex (VRTX) delivered earnings and revenue surprises of -0.25% and 5.16%, respectively, for the quarter ended December 2024. Do the…

These are the stocks posting the largest moves in extended trading.…

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis…

Investing in stocks that arent performing well can be a good move, but only if there are good reasons to…

…

Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the…

Vertex Pharmaceuticals SWOT analysis: biotech giants stock faces growth challenges…

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.…

Some people are fair-weather friends; others are lifelong. Its a similar story with stocks. Some you might hold only temporarily,…

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On…

Lately, one of Americas leading pharmaceutical companies cant catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX)…

…

Vertex Pharmaceuticals’ non-opioid painkiller comes without the potential risk of addiction.…

Die US-Arzneimittelbehörde FDA hat das das nicht-opioide Schmerzmittel von Vertex Pharmaceuticals zur Behandlung akuter Schmerzen zugelassen, wie die Gesundheitsbehörde am 30.01.2025…

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds. Rising interest…

Some people make it a New Years resolution to improve their finances by investing in stocks. Its a laudable goal,…

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds up…

Many products sold by companies arent must-have items. However, healthcare is a necessity. And the healthcare sector is poised to…

You can look at the momentum for some stocks and have a feeling that its about to end. Others, though,…